PURPOSE: Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients. In murine models of T-ALL, Notch-1 activation can both directly initiate leukemia and cooperate secondarily to other primary events. Whether acquisition of Notch-1 mutations is an early initiating event or a secondary event in the pathogenesis of human T-ALL is unclear. EXPERIMENTAL DESIGN: We used denaturing high-performance liquid chromatography, sequencing, and fragment analysis to analyze Notch-1 mutational status and mutant level in 62 patients at presentation as well as 16 matched presentation-relapse samples. RESULTS: We detected Notch-1 mutations in 47 patients (76%). Seven of these were low-level mutations (quantified at < or =10%), despite high blast counts, suggesting that they were acquired as a secondary event in a subclone. Of 16 matched presentation-relapse samples studied, 7 were wild-type at both presentation and relapse. Five of nine mutant-positive patients at presentation relapsed with the same mutation(s) at the same high level. Four patients had evidence of a change in mutant at relapse. One lost a PEST mutation and became wild-type. Two others lost mutations at relapse but acquired different mutations, despite unchanged T-cell receptor rearrangements, suggesting that the latter event predated the acquisition of the Notch-1 mutation. One relapsed with a secondary T-cell leukemia and different Notch mutation. CONCLUSIONS: These results suggest that Notch-1 mutations can sometimes be acquired as secondary events in leukemogenesis and must be used cautiously as solitary minimal residual disease markers.
PURPOSE: Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients. In murine models of T-ALL, Notch-1 activation can both directly initiate leukemia and cooperate secondarily to other primary events. Whether acquisition of Notch-1 mutations is an early initiating event or a secondary event in the pathogenesis of human T-ALL is unclear. EXPERIMENTAL DESIGN: We used denaturing high-performance liquid chromatography, sequencing, and fragment analysis to analyze Notch-1 mutational status and mutant level in 62 patients at presentation as well as 16 matched presentation-relapse samples. RESULTS: We detected Notch-1 mutations in 47 patients (76%). Seven of these were low-level mutations (quantified at < or =10%), despite high blast counts, suggesting that they were acquired as a secondary event in a subclone. Of 16 matched presentation-relapse samples studied, 7 were wild-type at both presentation and relapse. Five of nine mutant-positive patients at presentation relapsed with the same mutation(s) at the same high level. Four patients had evidence of a change in mutant at relapse. One lost a PEST mutation and became wild-type. Two others lost mutations at relapse but acquired different mutations, despite unchanged T-cell receptor rearrangements, suggesting that the latter event predated the acquisition of the Notch-1 mutation. One relapsed with a secondary T-cell leukemia and different Notch mutation. CONCLUSIONS: These results suggest that Notch-1 mutations can sometimes be acquired as secondary events in leukemogenesis and must be used cautiously as solitary minimal residual disease markers.
Authors: Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando Journal: Blood Date: 2009-06-03 Impact factor: 22.113
Authors: Wendy R Gordon; Monideepa Roy; Didem Vardar-Ulu; Megan Garfinkel; Marc R Mansour; Jon C Aster; Stephen C Blacklow Journal: Blood Date: 2008-12-15 Impact factor: 22.113
Authors: Monique Dail; Jason Wong; Jessica Lawrence; Daniel O'Connor; Joy Nakitandwe; Shann-Ching Chen; Jin Xu; Leslie B Lee; Keiko Akagi; Qing Li; Jon C Aster; Warren S Pear; James R Downing; Deepak Sampath; Kevin Shannon Journal: Nature Date: 2014-07-20 Impact factor: 49.962
Authors: Anica M Wandler; Benjamin J Huang; Jeffrey W Craig; Kathryn Hayes; Hannah Yan; Lauren K Meyer; Alessandro Scacchetti; Gabriela Monsalve; Monique Dail; Qing Li; Jasmine C Wong; Olga Weinberg; Robert P Hasserjian; Scott C Kogan; Philip Jonsson; Keith Yamamoto; Deepak Sampath; Joy Nakitandwe; James R Downing; Jinghui Zhang; Jon C Aster; Barry S Taylor; Kevin Shannon Journal: Leukemia Date: 2020-02-17 Impact factor: 11.528
Authors: Mark Y Chiang; Lanwei Xu; Olga Shestova; Gavin Histen; Sarah L'heureux; Candice Romany; M Eden Childs; Phyllis A Gimotty; Jon C Aster; Warren S Pear Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808